Fourth Quarter & Full Year 2022 Financial & Business Update

Building our Discovery Platform for the Short- and Long-Term Through New Technologies and Innovation Wave 3 ~1-3 yrs ADCs employing novel Auristatin and Camptothecin technologies Wave 4 -3-5 yrs ADCs incorporating new cytotoxic and immunostimulatory payloads Wave 5 ~5+ yrs Novel drug conjugate technologies employing diverse mechanisms of action Seagen 13

View entire presentation